146 related articles for article (PubMed ID: 3121888)
1. [Susceptibility of clinical bacterial isolates to aztreonam].
Murase M; Niiya T; Takeuchi N
Jpn J Antibiot; 1987 Sep; 40(9):1698-706. PubMed ID: 3121888
[TBL] [Abstract][Full Text] [Related]
2. [Susceptibility of clinical isolates to aztreonam].
Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
[TBL] [Abstract][Full Text] [Related]
3. [Susceptibility of clinically isolated strains to aztreonam].
Daimon Y
Jpn J Antibiot; 1988 Nov; 41(11):1623-34. PubMed ID: 3145344
[TBL] [Abstract][Full Text] [Related]
4. [Antibacterial activity of aztreonam against clinical isolates].
Igari J
Jpn J Antibiot; 1994 May; 47(5):502-20. PubMed ID: 8051793
[TBL] [Abstract][Full Text] [Related]
5. [Antibacterial activities of monobactams against fresh clinical isolates].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
[TBL] [Abstract][Full Text] [Related]
6. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987). III. Secular changes in susceptibility].
Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1990 Jun; 43(6):968-1136. PubMed ID: 2122041
[TBL] [Abstract][Full Text] [Related]
7. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
Qadri SM; Belobraydic KA
Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility].
Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
Jpn J Antibiot; 1986 Nov; 39(11):3019-93. PubMed ID: 3102809
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
Hamouche E; Sarkis DK
Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
[TBL] [Abstract][Full Text] [Related]
12. [Comparison between the activity of 2 amino-glycoside antibiotics, tobramycin and gentamicin on gram negative bacteria in vitro].
De Rosa F; Tassi C; Stagni GR
Ann Sclavo; 1974; 16(1):65-72. PubMed ID: 4214247
[No Abstract] [Full Text] [Related]
13. Antibacterial activity of aztreonam: a synthetic monobactam. A comparative study with thirteen other antibiotics.
Paradelis AG; Stathopoulos GA; Salpigides GN; Crassaris LG
Methods Find Exp Clin Pharmacol; 1983; 5(6):375-83. PubMed ID: 6684718
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
15. [Combined antibacterial activity of aztreonam and clindamycin against clinically isolated strains].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
Jpn J Antibiot; 1991 May; 44(5):529-37. PubMed ID: 1880932
[TBL] [Abstract][Full Text] [Related]
16. [In vitro examination on antibacterial activities of broad-spectrum antibiotics against gram-negative clinical isolates (author's transl)].
Deguchi K; Oda S; Sato Y; Ikeda Y; Nakamura T
Jpn J Antibiot; 1975 Dec; 28(6):785-94. PubMed ID: 1104913
[TBL] [Abstract][Full Text] [Related]
17. Multicenter in vitro comparison of piperacillin and nine other antibacterials against 1,629 clinical isolates.
Greenberg RN; Bowne DB; Gelfand M; Sathe SS
Clin Ther; 1990; 12(1):61-70. PubMed ID: 2183941
[TBL] [Abstract][Full Text] [Related]
18. [Susceptibility of clinical isolates to aztreonam].
Asari S; Horikawa M; Tsukamoto H; Kouda K; Hayashi C; Miyai K
Jpn J Antibiot; 1987 Jul; 40(7):1317-31. PubMed ID: 3479624
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). III. Secular changes in susceptibility].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Sep; 48(9):1174-263. PubMed ID: 7474335
[TBL] [Abstract][Full Text] [Related]
20. [Statistical observation on chronological changes of sensitivity of various bacteria to antibiotics. 1. Gram negative bacilli; Escherichia coli, Bacillus pneumoniae, Proteus vulgaris, Alcaligenes faecalis, Cloaca, Providencia, Citrobactor, Pseudomonas aeruginosa (1966-71)].
Fukazawa S; Ogi Kayoko Shimoama Y; Shimogaki F; Uete T
Nihon Rinsho; 1973 Feb; 31(2):457-65. PubMed ID: 4198261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
